6th Middle East Pharmacoeconomics and Drug Policy Summit Kicks Off in Riyadh
Under the theme “HTA Ignite: Real-World, Real-Impact,” the 6th Middle East Pharmacoeconomics and Drug Policy Summit (MEPDPS) is set to take place 18-19 April in Riyadh. The two-day leading event, organized by the Saudi Society of Clinical Pharmacy (SSCP), welcomes local, regional, and international speakers and top-notch experts in the fields of pharmacoeconomics and health technology.
The summit serves to advance the understanding of evidence-based assessments and the development of transparent frameworks for value-driven healthcare decisions across the Middle East. It will demonstrate how Health Technology Assessment (HTA) harnesses Real-World Data (RWD) to produce actionable Real-World Evidence (RWE). By assessing the clinical, economic, and societal impact of therapies, the summit aims to enable value-based pricing, improve access to advanced treatments, and promote sustainable healthcare practices throughout the region.
Dr. Ahmed Al Jedai, Summit Chairman and Founding President of the Saudi Society of Clinical Pharmacy (SSCP), stated: “As we mark the sixth consecutive year of the Pharmacoeconomics and Middle East Summit, this platform continues to grow in relevance and regional impact. Strengthening pharmacoeconomic capabilities and advancing value-based healthcare are no longer optional—they are essential to sustainable health systems. Riyadh stands today as a hub for evidence-driven dialogue, collaboration, and innovation that will shape the future of healthcare across the Middle East.”
Mohammed Alshennawi, Summit Vice Chair and General Director of Pharmaceutical Care at the Ministry of Health, KSA, highlighted the importance of the event, saying: “The 6th Middle East Pharmacoeconomics & Drug Policy Summit represents a pivotal opportunity to align pharmaceutical innovation with sustainable healthcare value. As the region advances toward more efficient health systems, evidence-based economic evaluation will be essential in ensuring patients receive timely access to transformative therapies while maintaining fiscal responsibility.”
The summit features a distinguished speaker faculty including Wejdan I. Aburas (Ministry of Health, KSA), Abeer Al Rabayah (King Hussein Cancer Center, Jordan), Abdulrazaq Al-Jazairi (King Faisal Specialist Hospital & Research Centre), Alaa Saeed Mutlaq (Ministry of Health KSA), Mohamed Alshennawi (Ministry of Health, KSA), Bashayr Alsuwayni (King Saud University Medical City, KSA), Shaikh Mohamed Ebrahim Alkhalifa (Supreme Council of Health, Bahrain), and Fatimah H. Alyami (Center of Health Technology Assessment, KSA). Over 350 delegates, including regulatory authorities, health economists, and industry leaders, are expected to attend the sessions held at the Crowne Plaza RDC.
For more information about the “6th Middle East Pharmacoeconomics and Drug Policy Summit,” please visit:
